Clinical trials: Endocrine, Nutritional, Metabolic and Immunity Disorders
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT01966393
- Testing
- 60-hours intervention
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Diabetes Type 1
The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans
Arterial vascular disease is the major cause of morbidity and mortality for Type 1 diabetic patients (DM1). Metabolic insulin resistance (metIR), even in the absence of hyperglycemia, conveys a 1.5 to 3-fold increased CVD risk in…
- Trial name
- EJB046 (NCT02490124)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Type 1 Diabetes
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes
The primary objective is to test the hypothesis that co-transplantation of allogeneic PTG with adult pancreatic islets (derived from same deceased donor) in the IM site in people with Type 1 diabetes with functioning kidney…
- Trial name
- PARADIGM (NCT03977662)
- Testing
- Co-transplantation of PTG with pancreatic islets
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Peter Stock
Diabetes Mellitus, Type 1
Development of a Comprehensive AP Training Curriculum for Adults
An e-learning training program is to prepare people with diabetes and their physicians on the use of UVA's Artificial Pancreas prototype -- Diabetes Assistant (DiAs).
- Trial name
- NCT02434094
- Testing
- eDAPT on-line training program
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Virginia
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Diabetes, Diabetes Mellitus, Type 1
French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients
This non-interventional study is conducted in Europe. The study is both retrospective and prospective. The purpose of the study is to assess the frequency of hypoglycaemia (low blood glucose) in insulin-treated patients with type…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DIALOG (NCT01628341)
- Testing
- insulin
- Where
- France
- Volunteers
- 4,424 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Visual Impairment
Pancreatic Islet Transplantation to the Anterior Chamber of the Eye
This is a phase II prospective, interventional, open-labeled, proof-of-concept study. 2 years per participant, 2 years 6 months in total Total n=6 The primary objective is to assess the safety of human pancreatic islet…
- Trial name
- EYELETS (NCT04198350)
- Testing
- Islet implantation
- Where
- United Kingdom
- Sponsor
- Imperial College London
Malaria, Schistosoma Mansoni
Leiden University Medical Center Mini Donor Bank
(Bio)medical research, particularly immunological, metabolic, transcriptional or biological assays, occasionally require the use of fresh blood (peripheral mononuclear cells) or urine.
- Conditions
- Malaria, Schistosoma Mansoni, Schistosoma Haematobium, Diabetes
- Trial name
- NCT02810613
- Volunteers
- healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
The SPEED study is a randomized, crossover pilot study evaluating the pharmacokinetics of novel insulin formulations in adults with type 1 diabetes.
- Trial name
- SPEED (NCT07090824)
- Testing
- Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Type 1 Diabetes Mellitus
Bolus Calculator and Wireless Communication With Blood Glucose Meter in Management of Type 1 Diabetes Mellitus (T1DM).
Bolus calculator (BC) is one of the advanced functions in modern insulin pumps (CSII)models. Together with wireless communication with blood glucose meter potentially facilitates achieving the target post prandial glucose levels.
- Trial name
- NCT01677546
- Testing
- CSII+BC+CL, CSII+BC
- Where
- Poland
- Volunteers
- 156 people
- Sponsor
- Medical University of Warsaw
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario
It is recommended that people with diabetes have their eyes screened for retinopathy every 1-2 years. Retinopathy can lead to visual impairment and blindness, but early detection through regular retinal screening can help to…
- Trial name
- TOP (NCT03927859)
- Testing
- a mail letter, a phone call and a phone call plus mailed letter
- Where
- 2 sites in Canada
- Volunteers
- 420 people
- Sponsor
- Women's College Hospital
Type 1 Diabetes Mellitus
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
The purpose of this study is to compare the safety and efficacy of MK-1293 to Lantus™ in participants with T1DM. The primary hypothesis is that after 24 weeks, the mean change in hemoglobin A1c (A1C) from baseline is non-inferior…
- Trial name
- NCT02059161
- Testing
- MK-1293, Lantus™, Prandial Insulin
- Volunteers
- 508 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes, Hypoglycemia
Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
Type 1 diabetes (T1D) results from destruction of insulin producing beta cells by the body's own immune system (autoimmunity) causing an individual to lose the ability to make enough insulin to control their blood sugar levels…
- Trial name
- MUGGLE (NCT05616273)
- Testing
- Mixed Meal Tolerance Test (MMTT), Arginine Stimulation Test (AST), Home Finger Prick Sample
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Exeter
Diabetes Mellitus, Type 1, Pediatric ALL
Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study
More than half of type 1 diabetes (DT1) children are under CSII (Continuous Subcutaneous Insulin Infusion). Several studies showed that despite a patients' follow-up mostly by hospital-based paediatricians, there are still some…
- Trial name
- DEEP (NCT04100070)
- Testing
- Monitoring of the patients
- Where
- France
- Volunteers
- 320 people
- Sponsor
- ISIS Diabete Service
Diabetes, Mellitus, Type 1
A Study About Patient Decision Aids Designed to Help Parents and Guardians in Canada Make Evidence-informed, Values-congruent Decisions About Screening Children for Type 1 Diabetes and Follow-up Decisions.
This study will design and test patient decision aids to help parents and guardians in Canada make decisions about screening their children for type 1 diabetes.
- Trial name
- NCT07317973
- Testing
- Web-based patient decision aid, Standard materials
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Laval University
Type 1 Diabetes Mellitus
Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
Primary Objective: to assess the relative bioavailability of a single dose of insulin glargine (Lantus) and lixisenatide given subcutaneously as on-site mix versus separate and simultaneous injections of each drug Secondary…
- Trial name
- NCT01146678
- Testing
- Insulin glargine HOE901, Lixisenatide AVE0010
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492218
- Testing
- biphasic human insulin 30
- Where
- Philippines
- Volunteers
- 1,330 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Feasibility and Safety Study of the Automated Insulin Delivery Closed Loop System Pancreas4ALL
Pilot prospective controlled monocentric open-label, randomized study evaluating the feasibility and safety of the Pancreas4All automated "closed loop" glycemic control system.
- Trial name
- ASAP (NCT04835350)
- Testing
- Pancreas4ALL - meal announcement or full closed loop
- Where
- Czechia
- Volunteers
- 16 people
- Sponsor
- Lenka Petruzelkova
Diabetes, Diabetes Mellitus, Type 1
The HEADWIND Study - Part 3
To analyse driving behavior of individuals with type 1 diabetes in eu- and mild hypoglycaemia using a validated research driving simulator.
- Trial name
- NCT05183191
- Testing
- Controlled hypoglycaemic state while driving with a driving simulator
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.